Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 6/20 | 0.40 |
| ▸ | IGF1R | P08069 | 6/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 2/20 | 0.39 |
| ▸ | CCND3 | P30281 | 2/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22942136 | 1.00 | INSR (0.40) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22942147 | 0.88 | MEN1 (0.42) | IGF1RALKEGFR | |
| SCHEMBL29876924 | 0.88 | MEN1 (0.42) | IGF1RALKEGFR | |
| SCHEMBL13832188 | 0.85 | CCNA2 (0.47) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL24940079 | 0.82 | ALK (0.44) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL30487108 | 0.82 | ALK (0.44) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22028008 | 0.81 | INSR (0.41) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22026163 | 0.80 | EGFR (0.51) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL30702793 | 0.80 | EGFR (0.51) | INSRIGF1RALKCDK9CCNA2 | |
| SCHEMBL22025893 | 0.80 | EGFR (0.52) | INSRIGF1RALKCDK9CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116888108-A | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2023-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | INSR 75/4885IGF1R 40/4885ALK 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.